Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2

Briony Shaw; Jake Shortt; Michael Low; Benjamin Rogers; Zane Kaplan; Pasquale Fedele; Gareth Gregory; Shahla Vilcassim; Michael Gilbertson; George Grigoriadis; Stephen Opat

doi:10.1111/imj.15954

Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2

Intern Med J. 2022 Dec;52(12):2172-2175. doi: 10.1111/imj.15954. Epub 2022 Nov 27.

Authors

Briony Shaw^{1

2}, Jake Shortt^{1

2}, Michael Low^{1

2}, Benjamin Rogers^{1

3}, Zane Kaplan^{1

2}, Pasquale Fedele^{1

2}, Gareth Gregory^{1

2}, Shahla Vilcassim^{1

2}, Michael Gilbertson^{1

2}, George Grigoriadis^{1

2}, Stephen Opat^{1

2}

Affiliations

¹ Department of Clinical Haematology, Monash Health, Melbourne, Victoria, Australia.
² Monash University, Melbourne, Victoria, Australia.
³ Department of Infectious Diseases, Monash Health, Melbourne, Victoria, Australia.

PMID: 36436197
DOI: 10.1111/imj.15954

Abstract

Coronavirus disease 2019 (COVID-19) infection in patients with haematological neoplasms has been associated with increased mortality; however, many studies in this patient group were reported early in the pandemic. The authors evaluated outcomes of COVID-19 infection in patients with haematological conditions following widespread vaccination, newer viral variants and increasingly effective antiviral therapies. A 4% mortality rate was found and contemporary risk factors for hospitalisation including older age, nonvaccination or partial COVID-19 vaccination status and infection with non-Omicron strain were identified.

Keywords: COVID-19; cancer; haematological malignancy; haematological neoplasm; vaccination.

MeSH terms

COVID-19 Vaccines
COVID-19*
Hematologic Neoplasms* / therapy
Hematology*
Humans
SARS-CoV-2

Substances

COVID-19 Vaccines